Following the news that Sanofi and Regeneron presented analyses from the LIBERTY AD PRESCHOOL (NCT03346434) study of interleukin (IL)-4/13 inhibitor, Dupixent (dupilumab), at the European Academy of Dermatology and Venereology (EADV) 2022;

Ramla Salad, Pharma Analyst at GlobalData, a leading data and analytics company, offers her view:

“Dupixent is proving to be very efficacious, even in the youngest of patients. It is expected to dominate the atopic dermatitis (AD) market, as there is no direct competition expected in the ≥6 months to five-year age group for several years. This gives Sanofi and Regeneron a steep market advantage. The results from the LIBERTY-AD PRESCHOOL trial will help the companies remain market leaders for the next five to ten years.

“According to GlobalData’s Pharma: Clinical Trials Database, I see that there will be an influx of novel therapies expected in the near-term, however, Sanofi and Regeneron’s long-term data and post-hoc analyses will allow these companies to defend and differentiate their gold standard biologic against competition in the AD space, allowing the companies to draw on the benefits shown in LIBERTY-AD PRESCHOOL.

“The analysis clearly demonstrates Dupixent’s rapid and consistent efficacy in the reduction of excoriation across all anatomic regions at Week 16. Not only did the results show significantly reduced excoriation across the anatomic regions verses placebo plus TCS (p<0.0001), but patients saw improvements as early as Week 2 (p<0.001). There were also significant improvements in erythema, and lichenification, papulation, as well as surface area involvement and body regions scores at Week 16 (p<0.0001).”